Navigation Links
Oral Transmucosal Drug Delivery. Products, Players, Markets & Forecasts
Date:3/19/2013

DUBLIN, Ireland, March 19, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "Oral Transmucosal Drug Delivery. Products, Players, Markets & Forecasts" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

In their search for alternative delivery methods that will enhance compliance and improve safety, drug developers and researchers are discovering that the permeability of mucous membranes provides a convenient route for the systemic delivery of new and existing therapeutic drugs. Transmucosal delivery offers the potential for once daily dosing of oral drugs and avoids the effects of first pass metabolism. On the provider side, the development of alternative methods of drug administration has improved the ability of physicians to manage specific problems. Practitioners now recognize the rapid onset, relative reliability, and the general lack of patient discomfort when drugs are administered by the transmucosal route. We expect this market to experience healthy growth through 2015 as buccal technology is applied to existing drugs and as transmucosal formulations become an important route of administration for an increasing number of new NCEs. Growth in this sector will also be driven by the pressure to extend market protection for numerous existing drugs with soon-to-expire patents.

Highlights:

- Analyzes and evaluates oral transmucosal drug delivery technology platforms and their impact on the market

- Analyzes oral transmucosal drug products and pipeline product candidates

- Provides assessments of key oral transmucosal drug therapeutic categories

- Provides market data and forecasts to 2016

- Profiles market participants, their product development activities and strategies

Key Topics Covered:

- Executive Summary
- Drug Delivery Market Dynamics
- Competing Transmucosal Delivery Technologies
- Commercial Transmucosal Formulation Platforms
- Oral Transmucosal Drug Technology Factors
- FDA-Approved Oral Transmucosal Products
- Important Pipeline Product Candidates
- Market Assessments & Forecasts
- Market Factors
- Market Participant Profiles

For more information, including full table of contents, please visit http://www.researchandmarkets.com/research/ltg5xz/oral_transmucosal

Research and Markets
Laura Wood , Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +1-353-1-481-1716
Sector: Drug Delivery



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Research Available on the Multi-Billion Dollar Transmucosal Drug Delivery and Systemic Nasal Sprays Markets
2. AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
3. AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
4. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
5. BIOCRATES Life Sciences to Launch Waters Xevo® TQ MS Editions for Two of its Well-established Research Kit Products, AbsoluteIDQ® p180 and p150
6. Transdermal Hormone Replacement: Products, Players, Markets and Forecasts
7. Global Information Inc Offers Big Discounts on Market Forecasts for Surgical Sealants, Wound Closure Products, Spine Surgery Technology, and More
8. Perrigo Company To Acquire Assets Of Sergeants Pet Care Products, Inc., For $285 Million
9. Transdermal Pain Management to 2016: Products, Markets, Forecasts and Opportunities
10. China Biologic Products, Inc. Adopts Stockholder Rights Plan
11. Wright Therapy Products, Inc. Closes $3 million Financing Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... SAN DIEGO and VANCOUVER, British Columbia, March 27, ... SPHS ) (the "Company" or "Sophiris"), a clinical ... treatment of patients with urological diseases, today reported ... and key corporate highlights. Key ... in Clinical Development for Localized Prostate Cancer. During ...
(Date:3/27/2017)... , March 27, 2017 /PRNewswire/ - INVICTUS MD ... IVITF; FRA: 8IS) Invictus MD is pleased to announce ... shares for trading on the TSX Venture Exchange.  ... TSXV follows a year of significant achievements for Invictus-MD. ... successful test crops at AB Laboratories Inc. ("AB Labs"), ...
(Date:3/27/2017)... , March 27, 2017 The ... reach USD 16.0 billion by 2025, according to a ... prevalence of chronic diseases is anticipated to be responsible ... which thereby widens the scope for growth during the ... bariatric population, which is highly susceptible to chronic diseases, ...
Breaking Medicine Technology:
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... ... Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer the recently ... balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s already comprehensive ...
(Date:3/28/2017)... ... March 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in people of ... a lot to offer to the discussion of dealing with excess skin oil. “Oily skin ... many home remedies that can help remove the oily shine while keeping the skin fresh ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... with or without a referral. Sleep apnea is often left untreated because patients are ... headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep ...
(Date:3/27/2017)... Philadelphia PA and London UK (PRWEB) , ... ... ... have the speed, agility and ability to gain site attention and engagement over ... DrugDev educational webinar will discuss how partnering with the ...
Breaking Medicine News(10 mins):